Year None202420232022202120202019201820172014 Nov 07, 2024 PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results Oct 23, 2024 PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial Aug 08, 2024 PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial May 30, 2024 PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June May 29, 2024 Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator May 09, 2024 PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights Mar 27, 2024 PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors Mar 18, 2024 PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer Feb 29, 2024 PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights Feb 26, 2024 PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
